|
 |
FoscarnetThis page contains recent news articles, when available, and an overview of Foscarnet but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Overview: Foscarnet (when available) Foscarnet is an organic analogue of inorganic pyrophosphate that inhibits replication of herpes viruses in vitro including cytomegalovirus (CMV) and herpes simplex virus types 1 and 2 (HSV-1 and HSV-2). Foscarnet does not require activation (phosphorylation) by thymidine kinase or other kinases and therefore is active in vitro against HSV TK deficient mutants and CMV UL97 mutants. Thus, HSV strains resistant to acyclovir or CMV strains resistant to ganciclovir may be sensitive to foscarnet. However, acyclovir or ganciclovir resistant mutants with alterations in the viral DNA polymerase may be resistant to foscarnet and may not respond to therapy with foscarnet. The combination of foscarnet and ganciclovir has been shown to have enhanced activity in vitro. For the treatment of CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS) and for treatment of acyclovir-resistant mucocutaneous HSV infections in immunocompromised patients. Mechanism Of Action: Foscarnet exerts its antiviral activity by a selective inhibition at the pyrophosphate binding site on virus-specific DNA polymerases at concentrations that do not affect cellular DNA polymerases. News Articles on Foscarnet ANX-201 Demonstrates a Unique Resistance Profile in Preclinical Tests - Mar 31, 2008 Foscarnet, the main metabolite of ANX-201, is approved by the FDA for use in immunocompromised patients with CMV retinitis and mucocutaneous FOXBusiness CMV Retinitis in Transplant Patients - Apr 11, 2008 Eight patients received induction therapy with IV ganciclovir or one received induction therapy with foscarnet for a median of 43 days, Renal and Urology News, Cytomegalovirus Infection in Paediatric Haemopoietic Stem Cell ... - Feb 26, 2008 Of ten patients who developed antigenemia, nine were treated with ganciclovir ± foscarnet and two of these patients developed CMV pneumonitis and died. Irish Medical Journal, CMV Retinitis in Transplant Patients - Feb 12, 2008 Eight patients received induction therapy with IV ganciclovir or one received induction therapy with foscarnet for a median of 43 days, Renal and Urology News, Zalcitabine Syrup (Zalcitabine capsule) Information - May 17, 2007 American Chronicle,Aminoglycosides, amphotericin, foscarnet: May increase risk of peripheral neuropathy and other zalcitabine toxicities caused by decreased clearance of ADVENTRX Awards Manufacturing Contract for ANX-201 (Thiovir(TM)) - Mar 28, 2007 Drug Newswire (press release),The HIV resistance profile of ANX-201 and foscarnet is unique among RTIs reflecting the distinct mechanism of action of this novel drug class. Contract manufacturing news in brief - Apr 3, 2007 In-PharmaTechnologist.com,According to Adventrix, the HIV resistance profile of ANX-201 and foscarnet is unique among RTIs due to the distinct mechanism of action of this novel drug Options for treating ganciclovir-resistant CMV discussed at IDSA ... Oct 16, 2006 The current options are the intravenous drugs ganciclovir (Cymevene), foscarnet (Foscavir) and cidofovir (Vistide), and the oral valganciclovir (Valcyte. ... -Aidsmap, Refractory cytomegalovirus infection successfully treated after ... Aug 15, 2006 2006 AUG 15 - (NewsRx.com) -- Foscarnet plus leflunomide successfully treats refractory cytomegalovirus infection following stem cell transplantation. ... -Therapeutics Daily (subscription) ADVENTRX Presents Broad Antiviral Activity for Thiovir Jun 22, 2006 Thiovir is a prodrug for foscarnet that delivers both the active drug TPFA (thiophosphonoformate) and the active metabolite PFA (foscarnet). ... -Yahoo! News Hospira Reports First-Quarter 2006 Results May 9, 2006 Launched the anti-infective foscarnet, the first of Hospira's generic injectable pharmaceutical product launches planned for 2006. ... - MSN Money ADVENTRX to Present Positive Thiovir Antiviral Activity Results Apr 26, 2006 Thiovir is a prodrug for foscarnet that delivers both the active drug TPFA (thiophosphonoformate) and the active metabolite PFA (foscarnet). ... - Yahoo! News ADVENTRX Presents Positive Thiovir Preclinical Results Apr 3, 2006 Thiovir is a broad spectrum antiviral and oral prodrug for foscarnet, a drug approved to treat opportunistic infections in HIV/AIDS patients. ... - Yahoo! News ADVENTRX Pharma Says Preclinical Studies Of Thiovir-zidovudine ... Apr 3, 2006 Thiovir is a broad spectrum antiviral and oral prodrug for foscarnet, a drug approved to treat opportunistic infections in HIV/AIDS patients. ... - Trading Markets ADVENTRX Announces Upcoming Scientific Conference Presentations Mar 28, 2006 Thiovir is a prodrug for foscarnet that delivers both the active drug TPFA (thiophosphonoformate) and the active metabolite PFA (foscarnet) in an oral ... - Yahoo! News ADVENTRX Pharma Says Thiovir-zidovudine Combination Pre-clinical ... Apr 3, 2006 The antiviral synergy between Thiovir and zidovudine was significantly more pronounced than antiviral activity of combinations of foscarnet and zidovudine ... - Trading Markets Adventrx antiviral shows promise against bird flu Mar 21, 2006 Thiovir is intended to deliver the benefits of the antiviral drug foscarnet, including broad spectrum antiviral activity, with the added benefit of improved ... - Pharmaceutical Business Review Proteins can help cells protect themselves from infection with HIV Mar 13, 2006 ...newly-infected cells to the drugs from the non-nucleoside inhibitor class – the anti-HIV drug efavirenz (Sustiva) and the drug foscarnet, which although ... - Aidsmap Brand Names/Synonyms: Foscarnet is also known by the following brand names and/or synonymsCarboxyphosphonic Acid; Dihydroxyphosphinecarboxylic Acid Oxide; FOSCARNET; FOSCARNET SODIUM; Formic Acid, Phosphono-; Forscarnet Sodium; Foscarmet; Foscarnet; Foscarnet Sodium; Foscavir; PFA; Phgosphonocarboxylic Acid; Phosphonoformate; Phosphonoformic Acid; Triapten Drug Category: Foscarnet is categorized under the following by the FDA: Antivirals; Reverse Transcriptase Inhibitors; ATC:J05AD01 Dosage Forms: INJECTION Absorption: Poorly absorbed after oral administration (bioavailability from 12 to 22%). Interactions: -->Interactions for Foscarnet: A possible drug interaction of FOSCAVIR and intravenous pentamidine has been described. Concomitant treatment of four patients in the United Kingdom with FOSCAVIR and intravenous pentamidine may have caused hypocalcemia; one patient died with severe hypocalcemia. Toxicity associated with concomitant use of aerosolized pentamidine has not been reported. Because of foscarnet's tendency to cause renal impairment, the use of FOSCAVIR should be avoided in combination with potentially nephrotoxic drugs such as aminoglycosides, amphotericin B and intravenous pentamidine unless the potential benefits outweigh the risks to the patient. Abnormal renal function has been observed in clinical practice during the use of FASCAVIR and ritonavir, or FOSCAVIR, ritonavir, and saquinavir. Since FOSCAVIR decreases serum concentrations of ionized calcium, concurrent treatment with other drugs known to influence serum calcium concentrations should be used with particular caution. Ganciclovir The pharmacokinetics of foscarnet and ganciclovir were not altered in 13 patients receiving either concomitant therapy or daily alternating therapy for maintenance of CMV disease. Chemical IUPAC Name: phosphonomethanoicacid : |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines mongabay.com
COPYRIGHT 2007 MONGABAY.COM |